Jeil Pharma Holdings Past Earnings Performance
Past criteria checks 0/6
Jeil Pharma Holdings's earnings have been declining at an average annual rate of -13.4%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 11.5% per year.
Key information
-13.4%
Earnings growth rate
-16.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 11.5% |
| Return on equity | -3.3% |
| Net Margin | -2.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23
Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Revenue & Expenses BreakdownBeta
How Jeil Pharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 804,043 | -16,250 | 147,627 | 46,038 |
| 30 Sep 23 | 790,514 | -61,754 | 145,360 | 40,321 |
| 30 Jun 23 | 791,025 | -61,890 | 146,001 | 38,144 |
| 31 Mar 23 | 805,169 | -62,525 | 146,684 | 36,743 |
| 31 Dec 22 | 792,965 | -74,556 | 146,465 | 41,566 |
| 30 Sep 22 | 788,177 | -9,373 | 150,415 | 41,468 |
| 30 Jun 22 | 791,598 | -7,970 | 148,398 | 45,699 |
| 31 Mar 22 | 771,045 | -6,572 | 149,831 | 42,744 |
| 31 Dec 21 | 762,568 | -3,482 | 149,808 | 39,673 |
| 30 Sep 21 | 767,983 | 6,564 | 147,732 | 37,275 |
| 30 Jun 21 | 759,041 | 7,141 | 149,733 | 31,719 |
| 31 Mar 21 | 759,246 | 8,169 | 146,116 | 28,882 |
| 31 Dec 20 | 761,997 | 11,431 | 144,505 | 24,731 |
| 30 Sep 20 | 757,246 | -88,013 | 146,364 | 25,277 |
| 30 Jun 20 | 749,593 | -87,489 | 144,900 | 22,986 |
| 31 Mar 20 | 741,802 | -87,956 | 143,019 | 22,036 |
| 31 Dec 19 | 731,805 | -90,492 | 140,488 | 22,452 |
| 30 Sep 19 | 641,560 | 8,346 | 120,170 | 18,776 |
| 30 Jun 19 | 475,939 | 7,946 | 92,390 | 14,071 |
| 31 Mar 19 | 306,884 | 7,314 | 65,909 | 9,977 |
| 31 Dec 18 | 142,736 | 7,070 | 40,997 | 4,512 |
| 30 Sep 18 | 64,032 | 110,929 | 30,582 | 1,088 |
| 30 Jun 18 | 59,708 | 7,159 | 26,920 | 1,134 |
| 31 Mar 18 | 53,134 | 5,289 | 23,148 | 659 |
| 31 Dec 17 | 48,236 | 5,036 | 19,594 | 701 |
| 30 Sep 17 | 43,657 | -102,540 | 13,539 | 1,400 |
| 30 Jun 17 | 41,355 | 947 | 12,537 | 1,335 |
| 31 Mar 17 | 40,824 | 1,610 | 11,272 | 1,329 |
| 31 Dec 16 | 40,604 | 2,178 | 10,513 | 1,554 |
| 31 Dec 15 | 594,716 | 9,761 | 104,910 | 20,299 |
| 30 Sep 13 | 432,975 | 2,562 | 104,556 | 0 |
| 30 Jun 13 | 425,864 | 6,326 | 105,535 | 0 |
Quality Earnings: A002620 is currently unprofitable.
Growing Profit Margin: A002620 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A002620 is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare A002620's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A002620 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A002620 has a negative Return on Equity (-3.29%), as it is currently unprofitable.